SCHEMBL4833733

SCHEMBL4833733

CN(C(=O)Nc1cc(C(F)(F)F)ccc1F)c1ccc(N2CN=c3sccc3=C2N)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDR P35968 10/20 0.36
▸ UBE2M P61081 1/20 0.36
▸ DCUN1D1 Q96GG9 1/20 0.36
▸ CSF1R P07333 3/20 0.35
▸ PDGFRB P09619 2/20 0.34
▸ LCK P06239 6/20 0.34
▸ KIT P10721 2/20 0.34
▸ FGFR1 P11362 2/20 0.34
▸ FLT1 P17948 2/20 0.34
▸ FGFR3 P22607 2/20 0.34
▸ FLT3 P36888 2/20 0.34
▸ SRPK1 Q96SB4 2/20 0.34
▸ PLK4 O00444 1/20 0.34
▸ AURKA O14965 1/20 0.34
▸ MAPK13 O15264 1/20 0.34
▸ PDPK1 O15530 1/20 0.34
▸ DAPK3 O43293 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826371 0.85 CA12 (0.50) KDRCSF1RPDGFRBLCKKIT
SCHEMBL4833807 0.79 RET (0.43) KDRPDGFRBLCKJAK2RET
SCHEMBL4826389 0.79 KDR (0.32) KDR
SCHEMBL4828956 0.77 CSF1R (0.41) KDRCSF1RLCKCA1CA2
SCHEMBL4831096 0.76 TP53 (0.48) MEN1KMT2AKDRFLT1NTRK1
SCHEMBL4836357 0.74 MAPT (0.39) MEN1KMT2AKDRUBE2MDCUN1D1
SCHEMBL4833729 0.73 MEN1 (0.35) MEN1TSHRKMT2AKDRUBE2M
SCHEMBL4825658 0.73 KDR (0.50) MEN1KMT2AKDRCSF1RLCK
SCHEMBL4831108 0.73 ALDH1A1 (0.33) TSHR
SCHEMBL4836418 0.72 CSF1R (0.39) CSF1RABL1NTRK1MKNK2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MEN1 303/4885TSHR 3073/4885KMT2A 324/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MEN1 1454/4885TSHR 3243/4885KMT2A 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback